IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Kieran MURPHY)	
	:	Examiner: Vy Q. Bui
Application No.: 10/727,667)	•
	:	Group Art Unit: 3731
Filed: December 5, 2003)	-
	:	Confirmation No.: 8478
Title: DEVICE VIEWABLE UNDER AN)	
IMAGING BEAM	:	November 16, 2006
)	

Mail Stop: <u>Amendment</u> Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

THIRD INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed forms PTO/SB/08A and PTO/SB/08B.

FORMAL MATTERS

In accordance with 37 C.F.R. § 1.97(b)(3), since a first Office Action on the

merits of the subject application has not yet been issued, neither a certificate, petition nor

payment of a fee is believed to be required for this Information Disclosure Statement. However,

the Commissioner is hereby authorized to charge any fee which may be required in connection

with this paper to Deposit Account No. 50-1710.

CONCLUSION

It is respectfully requested that the above information be considered by the

Examiner and that a copy of the enclosed Forms PTO/SB/08A and PTO/SB/08B be returned

indicating that such information has been considered.

Applicants' undersigned attorney may be reached in our Washington, D.C.

office by telephone at (202) 625-3500. All correspondence should continue to be directed to our

address given below.

Respectfully submitted,

Áttorney for Applicants

Richard P. Bauer

Registration No. 31,588

PATENT ADMINISTRATOR KATTEN MUCHIN ROSENMAN LLP East Lobby, Suite 700 1025 Thomas Jefferson Street, N.W. Washington, D.C.

Facsimile: (202) 298-7570

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

December 5, 2003

3731

MURPHY, Kieran P.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO Application Number 10/727,667

Filing Date

Art Unit

First Named Inventor

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Examiner Name BUI. VY Q. Attorney Docket Number 331202.00008 Sheet 1 of |6

Examiner	Cite	Document Number	Publication Date	DOCUMENTS Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Dooming Hambel	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant
		Number-Kind Code ^{2 (if known)}			Figures Appear
	1	^{US-} 2004/073286 A1	04-15-2004	Armstrong et al.	
	2	^{US-} 6,533,806 B1	03-18-2003	Sullivan et al.	
	3	^{US-} 2002/052640 A1	05-02-2002	Bigus et al.	
	4	^{US-} 5,980,565 A	11-09-1999	Jayaraman et al.	
	5	^{US-} 6,179,878 B1	01-30-2001	Duerig et al.	
	6	^{US-} 2004/176833 A1	09-09-2004	Pavcnik et al.	
	7	^{US-} 6,352,561 B1	03-05-2002	Leopold et al.	
	8	^{US-} 4,733,665	03-29-1988	Palmaz	
***************************************	9	^{US-} 4,739,762	04-26-1988	Palmaz	
	10	^{US-} 4,776,337	10-11-1988	Palmaz	
	11	^{US-} 4,795,458	01-03-1989	Regan	
	12	^{US-} 4,994,066	02-19-1991	Voss	
	13	^{US-} 5,037,427	08-06-1991	Harada et al.	
	14	^{US-} 5,064,435	11-12-1991	Porter	
***************************************	15	^{US-} 5,067,957	11-26-1991	Jervis	***************************************
	16	^{US-} 5,102,417	04-07-1992	Palmaz	
	17	^{US-} 5,403,341	04-04-1995	Solar	
		US-			
		US-			

		FORE	IGN PATENT DOCL	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ -Kind Code ⁵ (<i>if known</i>)		Or Relevant Figures Appear	T ⁶	
	18	EP 1 155 689 A2	11-21-2001	Angiotech Pharmaceuticals		
	19	EP 0 797 988 A2	10-01-1997	Angiotech Pharmaceuticals		
	20	DE 3918736	12-13-1990	Vallbracht		
	21	EP 0809998 A2	12-03-1997	Cordis Corp.		
	22	EP 0578998	10-08-1997	Strecker		
	23	WO 98/26731	06-25-1998	Atrium Medical Corp.		

Examiner		Date	
Signature		Considered	
	i i		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document wilPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/727,667 Filing Date December 5, 2003 INFORMATION DISCLOSURE First Named Inventor MURPHY, Kieran P. STATEMENT BY APPLICANT Art Unit 3731 (Use as many sheets as necessary) Examiner Name BUI, VY Q. Attorney Docket Number 331202.00008 of Sheet

		***************************************	U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	24	^{US-} 5,522,881	06-04-1996	Lentz	
	25	^{US-} 5,522,882	06-04-1996	Gaterud et al.	
	26	^{US-} 5,549,635	08-27-1996	Solar	
	27	^{US-} 5,556,414	09-17-1996	Turi	
	28	^{US-} 5,562,726	10-08-1996	Chuter	
	29	^{US-} 5,591,195	01-07-1997	Taheri et al.	
	30	^{US-} 5,607,467	03-04-1997	Froix	
	31	^{US-} 5,725,572	03-10-1998	Lam et al.	
	32	^{US-} 5,735,892	04-07-1998	Myers et al.	
	33	^{US-} 5,741,333	04-21-1998	Frid	
	34	^{US-} 5,746,765	05-05-1998	Kleshinski et al.	
	35	^{US-} 5,772,669	06-30-1998	Vrba	
	36	^{US-} 5,788,626	08-04-1998	Thompson	
	37	^{US-} 5,788,707	08-04-1998	Del Toro et al.	
	38	^{US-} 5,797,952	08-25-1998	Klein	
	39	^{US-} 5,800,517	09-01-1998	Anderson et al.	
	40	^{US-} 5,810,870	09-22-1998	Myers et al.	
	41	^{US-} 5,824,045	10-20-1998	Alt	
	42	^{US-} 5,861,033	01-19-1999	Martakos et al.	

	Cite No.1			Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
			MM-DD-YYYY		Or Relevant Figures Appear	די		
	43	EP 947204 A2	10-06-1999	Cordis Corp.				
	44	WO 00/24338	05-04-2000	Medinol Ltd. et al.		I		
	45	EP 0947204	12-20-2000	Cordis Corp.				
						Ŀ		
						Γ		

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO Application Number 10/727,667 Filing Date December 5, 2003 INFORMATION DISCLOSURE First Named Inventor MURPHY, Kieran P. STATEMENT BY APPLICANT Art Unit 3731 (Use as many sheets as necessary) Examiner Name BUI, VY Q. Attorney Docket Number 331202.00008 Sheet 3 of.

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	46	^{US-} 5,876,448	03-02-1999	Thompson et al.	
	47	^{US-} 5,922,020	07-13-1999	Klein et al.	
	48	^{US-} 5,925,074	07-20-1999	Gingras et al.	
	49	^{US-} 6,010,529	01-04-2000	Herweck et al.	
	50	^{US-} 6,086,610	07-11-2000	Duerig	
	51	^{US-} 6,270,523 B1	08-07-2001	Herweck et al.	
	52	^{US-} 6,315,791 B1	11-13-2001	Gingras	
	53	^{US-} 2001/0041928 A1	11-15-2001	Pavcnik et al.	
	54	^{US-} 6,423,089 B1	07-23-2002	Gingras et al.	
	55	^{US-} 6,447,540	09-10-2002	Fontaine et al.	
	56	^{US-} 6,475,234 B1	11-05-2002	Richter	
	57	^{US-} 6,656,213	12-02-2003	Solem	
	58	^{US-} 6,740,113	05-25-2004	Vrba	
	59	^{US-} 2004/0148000	07-29-2004	Bilge	
-	60	us- 2004/0176835	09-09-2004	Vrba	
		US-			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known) MM-DD-YYYY	,,	Or Relevant Figures Appear	T ⁶		
						_	
						┡	

Examiner	De	ate	
Signature	Co	onsidered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
Cabattat				Application Number	10/727,667	
INF	ORMATION	DIS	CLOSURE	Filing Date	December 5, 2003	
STA	STATEMENT BY APPLICANT			First Named Inventor	MURPHY, Kieran P.	
	// lea as many she	ote ar a	acaecand	Art Unit	3731	
	(Use as many sheets as necessary)			Examiner Name	BUI, VY Q.	
Sheet	4	of	6	Attorney Docket Number	331202.00008	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	61	Dr. Hans-Ulrich Laasch et al., "Revision Notes for the FRCR Part 1", The Society of Radiologists in Training, 1999 (60 pages)	
	62	A.C. Kak and Malcolm Slaney, "Principles of Computerized Tomographic Imaging", Chapter 4 (Measurement of Projection Data-The Nondiffracting Case), pp. 113-134, IEEE, 1988 (22 pages)	
	63	Anthony R. Kovscek et al., "Stanford University Petroleum Research Institute Preliminary Twenty-Fourth Annual Report", April 19-21, 2001 (68 pages)	
	64	Google's Cache of http://www.bicetre.neuroradio.net/french/journal/menu.htm. at http://www.google.com/search?q=cacheU20QRBv7hYC; www.bicetre.neuroradio.net/french/journal/menu.htm+MCTA+angiography&hl=en&ie+UTF8, Index MARS 2002 (5 pages)	
	65	Gailloud, P.; Hillis, A.; Perler, B.; and Murphy, K.J. "Vertebrobasilar Stroke as a Late Complication of a Blalock-Taussig Shunt", Wiley-Liss, Inc., 2002, pp. 231-234 (4 pages)	
	66	Google's Cache of http://www.google.ca/search?q=%houndsfield+unit% 22&ie=UTF-8&oe=UTF8&hl=en&meta=, March 21, 2003 (60 pages)	A Committee of the Comm
	67	Dolmatch, Bart, M.D., et al., "Patency and Tissue Response Related to Two Types of Polytetrafluoroethylene-Covered Stents in the Dog," Journal of Vascular and Interventional Radiology, Vol. 7, No. 5, September-October 1996, pp.642-649 (9 pages)	
	68	Michael Strotzer, MD, et al., "Appearance of Vascular Stents in Computed Tomographic Angiography: In Vitro Examination of 14 Different Stent Types," Investigative Radiology, Vol. 36: (11) p. 652-658, November 2001, (6 pages)	
	69	Stefan Hahnel, et al., "Small-Vessel Stents for Intracranial Angioplasty: In Vitro Comparison of Different Stent Designs and Sizes by Using CT Angiography," AJNR Am J Neuroradiol 24:1512-1516, September 2003 (6 pages)	
	70	David Maintz, et al., "Revealing In-Stent Stenoses of the Iliac Arteries: Comparison of Multidetector CT with MR Angiography and Digital Radiographic Angiography in a Phantom Model," AJR:179, p. 1319-1322, November 2002 (4 pages)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Panerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			COTTOOS, NO DEISONS AT	Complete if Known		
				Application Number	10/727,667	
INFO	RMATION	DIS	CLOSURE	Filing Date	December 5, 2003	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	MURPHY, Kieran P.	
(Use as many sheets as necessary)				Art Unit	3731	
(ose as many sheets as necessary)			cocaaary)	Examiner Name	BUI, VY Q.	
Sheet	5	of	6	Attorney Docket Number	331202.00008	

	.	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	71	Henry Brem, et al., "Polymer-Based Drug Delivery to the Brain," Science & Medicine, Inc., Vol. 3, No. 4, p.1-11, July/August 1996 (11 pages)	
	72	Stephen Schroeder, et al., "Influence of Heart Rate on Vessel Visibility in Noninvasive Coronary Angiography Using New Multislice Computed Tomography Experience in 94 Patients," Journal of Clinical Imaging 26 (2002), p.106-107, 2002 (2 pages)	
	73	Paul P. Wang, et al., "Local Drug Delivery to the Brain," Advanced Drug Delivery Review 54 (2002), p. 987-1013, 2002 (27 pages)	
	74	Antezanna DF, et al., "High-dose Ibuprofen for reduction of striatal infarets during middle cerebral artery occlusion in rats," http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=PubMed&list_uids +12691413&dopt=Abstract; last visited on 10/01/2003 (2 pages)	
	75	Patrik Gabikian, MD, et al., "Stroke: Prevention of Experimental Cerebral Vasospasm by Intracranial Delivery of a Nitric Oxide Donor From a Controlled-Release Polymer," http://stroke.ahajournals.org/cgi/content/full/33/11/2681, last visited on 10/01/2003 (11 pages)	
	76	Travis S. Tierney, et al., "Prevention and Reversal of Experimental Posthemorrhagic Vasospasm by the Periadventitial Administration of Nitric Oxide From a Controlled-release Polymer," http://www.neurosurgery-online/fulltext/4904/0945/NURO49040945_doc.html, Vol. 49, No. 4, October 2001 (11 pages)	
	77	Rafael J. Tamargo, et al., "The Intracerebral Administration of Phenytoin Using Controlled-Release Polymers Reduces Experimental Seizures in Rats," Epilepsy Research 48, p. 145-155; 2002 (11 pages)	
	78	J. Golzarian, "Imaging After Endovascular Repair of Abdominal Aortic Aneurysm," Abdominal Imaging 28, p.236-243, 2003 (8 pages)	
	79	Jens Rodenwaldt, "Multislice Computed Tomography of the Coronary Arteries," Eur Radiol (2003) 13:748-757, January 2003 (10 pages)	
	80	Stefanie Weigel, et al., "Thoracic Aortic Stent Graft: Comparison of Contrast-Enhanced MR Angiography and CT Angiography in the Follow-Up: Initial Results," Eur Radiol (2003) 13:1628-1634, February 2003 (7 pages)	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions deviced this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/727,667	
INF	ORMATION	DIS	CLOSURE	Filing Date	December 5, 2003	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	MURPHY, Kieran P.	
(Use as many sheets as necessary)			acaecani)	Art Unit	3731	
			ecessary,	Examiner Name	BUI, VY Q.	
Sheet	6	of	6	Attorney Docket Number	331202.00008	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	81	Quoc-Anh Thai, BA, et al., "Inhibition of Experimental Vasospasm in Rats with the Periadventital Administration of Ibuprofen Using Controlled-Release Polymers," published by American Heart Association, p.140-147, January 1999 (8 pages).	
	82	Langer R. Brem, et al., "Biocompatibility of Polymeric delivery systems for macromolecules," http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7348718&dopt=Abstract, last visited on 10/31/2003 (1 page)	
	83	H. Brem, et al., "Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain," http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2772427&dopt=Abstract, last visited on 10/03/2003 (1 page)	
	84	Seung-Jung Park, M.D., et al., "A Paclitaxel-Eluting Stent for the Prevention of Coronary Restenosis," The New England Journal of Medicine, Vol. 348:1537-1545, Number 16, April 17, 2003, (3 pages)	
	85	Allan W. Heldman, MD, et al., "Paclitaxel Stent Coating Inhibits Neointimal Hyperplasia at 4 weeks in a Porcine Model of Coronary Restenosis," published by American Heart Association, Inc., p. 2289-2295, May 2001 (7 pages)	
	86	Jonette Foy, Ph.D., "Drug-Eluting Stents: Pre-Clinical Standards & Recommended Studies," FDA/SIR Device Forum Meeting, November 2002 (7 pages)	
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
1.314.113.114.114.11			

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.